Tyrosine kinase inhibitors

Exelixis to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021

Retrieved on: 
Thursday, July 22, 2021
Oncology, Health, Genetics, Clinical trials, Pharmaceutical, Biotechnology, Chemical compounds, Organic compounds, Orphan drugs, Drugs, Tyrosine kinase inhibitors, Cyclopropanes, Quinolines, Cabozantinib, Exelixis, Cobimetinib, NASDAQ, Daiichi Sankyo

Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2021 financial results will be released on Thursday, August 5, 2021 after the markets close.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2021 financial results will be released on Thursday, August 5, 2021 after the markets close.
  • At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update.
  • For more information about Exelixis, please visit www.exelixis.com , follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Exelixis to Present at the Virtual William Blair Biotech Focus Conference on July 15, 2021

Retrieved on: 
Thursday, July 8, 2021
Oncology, Health, Other Health, General Health, Pharmaceutical, Biotechnology, Chemical compounds, Organic compounds, Orphan drugs, Drugs, Tyrosine kinase inhibitors, Exelixis, Cyclopropanes, Quinolines, Cabozantinib, Cobimetinib, Daiichi Sankyo, NASDAQ

Exelixis, Inc. (Nasdaq: EXEL) today announced that Peter Lamb, Ph.D., the companys Executive Vice President, Scientific Strategy and Chief Scientific Officer, will present at the virtual William Blair Biotech Focus Conference 2021 on Thursday, July 15th at 2:00 p.m. EDT / 1:00 p.m. CDT / 11:00 a.m. PDT.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) today announced that Peter Lamb, Ph.D., the companys Executive Vice President, Scientific Strategy and Chief Scientific Officer, will present at the virtual William Blair Biotech Focus Conference 2021 on Thursday, July 15th at 2:00 p.m. EDT / 1:00 p.m. CDT / 11:00 a.m. PDT.
  • Exelixis is a member of the Standard & Poors (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies.
  • For more information about Exelixis, please visit www.exelixis.com , follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Global Kinase Inhibitors Market Report 2021: Data from 2019, 2020 Estimates for 2021 and Projections of CAGRs Through 2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 1, 2021
Biotechnology, Pharmaceutical, Health, Protein kinase inhibitors, Lactams, Tyrosine kinase inhibitors, Drugs, Morpholines, Enzyme inhibitors

The global market for kinase inhibitors should grow from $57.6 billion in 2021 to $79.2 billion by 2026 with a compound annual growth rate (CAGR) of 6.6% for the period of 2021-2026.

Key Points: 
  • The global market for kinase inhibitors should grow from $57.6 billion in 2021 to $79.2 billion by 2026 with a compound annual growth rate (CAGR) of 6.6% for the period of 2021-2026.
  • This report is designed to be a business tool that will provide a thorough evaluation of the markets for kinase inhibitors.
  • Various types of kinase inhibitors have been analyzed in the report, and along with their different application scenarios, the scope of this study includes regulatory aspects, pipeline analysis and demand for kinase inhibitors.
  • The market for kinase inhibitor market is experiencing an increasing demand for a number of novel kinase inhibitors being utilized in human trials.

InnoCare Announces Breakthrough Therapy Designation of Orelabrutinib by US FDA for Treatment of R/R MCL

Retrieved on: 
Monday, June 28, 2021
Tyrosine kinases, Bruton's tyrosine kinase, Branches of biology, Tyrosine kinase, Mantle cell lymphoma, Tyrosine kinase inhibitors, Orphan drugs, Drugs

BEIJING, June 28, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib for the treatment of relapsed or refractory mantle cell lymphoma (R/R MCL).

Key Points: 
  • BEIJING, June 28, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib for the treatment of relapsed or refractory mantle cell lymphoma (R/R MCL).
  • Orelabrutinib is a highly selective BTK inhibitor targeting both B-cell malignancy and autoimmune diseases.
  • Dr. Jasmine Cui, the co-founder, chairwoman and CEO of InnoCare said, "We are very proud that orelabrutinib was granted BTD after obtaining Orphan Drug Designation.
  • InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases.

Exelixis and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previously Untreated Advanced Liver Cancer

Retrieved on: 
Monday, June 28, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Chemical compounds, Orphan drugs, Drugs, Organic compounds, Antineoplastic drugs, Tyrosine kinase inhibitors, Cabozantinib, Cyclopropanes, Quinolines, Exelixis, Ipsen, Sorafenib, COSMIC-312, HCC, CABOMETYX® (cabozantinib), Ipsen, COSMIC-312, HCC, CABOMETYX® (CABOZANTINIB), IPSEN

Patients were randomized approximately 2:1:1 to one of three arms: cabozantinib (40 mg) in combination with atezolizumab, sorafenib, or cabozantinib (60 mg).

Key Points: 
  • Patients were randomized approximately 2:1:1 to one of three arms: cabozantinib (40 mg) in combination with atezolizumab, sorafenib, or cabozantinib (60 mg).
  • In the European Union, CABOMETYX is also approved in combination with nivolumab as first line treatment for patients living with advanced RCC.
  • In 2016, Exelixis granted Ipsen exclusive rights for the commercialization and further clinical development of cabozantinib outside of the United States and Japan.
  • The incidence of Grade 3 to 5 hemorrhagic events was 5% in CABOMETYX patients in RCC and HCC studies.

Exelixis and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previously Untreated Advanced Liver Cancer

Retrieved on: 
Monday, June 28, 2021
Research, FDA, Clinical trials, Other Health, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Chemical compounds, Orphan drugs, Drugs, Organic compounds, Antineoplastic drugs, Tyrosine kinase inhibitors, Cabozantinib, Cyclopropanes, Quinolines, Exelixis, Ipsen, Sorafenib, COSMIC-312, HCC, CABOMETYX® (cabozantinib), Ipsen, COSMIC-312, HCC, CABOMETYX® (CABOZANTINIB), IPSEN

Patients were randomized approximately 2:1:1 to one of three arms: cabozantinib (40 mg) in combination with atezolizumab, sorafenib, or cabozantinib (60 mg).

Key Points: 
  • Patients were randomized approximately 2:1:1 to one of three arms: cabozantinib (40 mg) in combination with atezolizumab, sorafenib, or cabozantinib (60 mg).
  • In the European Union, CABOMETYX is also approved in combination with nivolumab as first line treatment for patients living with advanced RCC.
  • In 2016, Exelixis granted Ipsen exclusive rights for the commercialization and further clinical development of cabozantinib outside of the United States and Japan.
  • The incidence of Grade 3 to 5 hemorrhagic events was 5% in CABOMETYX patients in RCC and HCC studies.

HUTCHMED announces savolitinib approved in China for patients with lung cancer with MET exon 14 skipping alterations

Retrieved on: 
Tuesday, June 22, 2021
Tyrosine kinase receptors, Lung cancer, Organic compounds, Quinazolines, Chemical compounds, Non-small-cell lung carcinoma, Tyrosine kinase, C-Met, Branches of biology, Tyrosine kinase inhibitors, Chloroarenes, Icotinib

Approximately 2-3% of newly diagnosed NSCLC patients have MET exon skipping 14 alterations, a specific genetic mutation.

Key Points: 
  • Approximately 2-3% of newly diagnosed NSCLC patients have MET exon skipping 14 alterations, a specific genetic mutation.
  • Savolitinib is an oral, potent and selective MET TKI that has demonstrated clinical activity in advanced solid tumors.
  • It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations).
  • HUTCHMED is responsible for the manufacturing and supply of savolitinib, and AstraZeneca is responsible for its commercialization in China and worldwide.

Global Mantle Cell Lymphoma Clinical Landscape Market Report 2021: Marketed and Pipeline Drugs, Trials, Key Events, Success Probability, 10-Year Disease Prevalence Forecast, Deals, Revenue Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 17, 2021
Pharmaceutical, Health, Oncology, Non-Hodgkin lymphoma, Hematology, Mantle cell lymphoma, Medical specialties, Lymphoma, MCL, Branches of biology, Clinical medicine, Tyrosine kinase inhibitors, Entospletinib

The "Market Spotlight: Mantle Cell Lymphoma" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Spotlight: Mantle Cell Lymphoma" report has been added to ResearchAndMarkets.com's offering.
  • This Market Spotlight report covers the Mantle Cell Lymphoma (MCL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
  • The publisher estimates that in 2017, there were approximately 14,030 incident cases of mantle cell lymphoma (MCL) worldwide, and forecasts that number to increase to 18,010 incident cases by 2026.
  • Johnson & Johnson leads industry sponsors with the highest overall number of clinical trials for MCL, followed by Bristol Myers Squibb.

New Phase 3 Study Results Show IMBRUVICA® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia

Retrieved on: 
Saturday, June 12, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Chemical compounds, Organic compounds, Drugs, Orphan drugs, Breakthrough therapy, Tyrosine kinase inhibitors, Antineoplastic drugs, Ibrutinib, Pyrazolopyrimidines, Chronic lymphocytic leukemia, Venetoclax, Obinutuzumab

Mantle cell lymphoma (MCL): As a single agent for the treatment of adult patients with relapsed or refractory MCL.

Key Points: 
  • Mantle cell lymphoma (MCL): As a single agent for the treatment of adult patients with relapsed or refractory MCL.
  • Waldenstrms macroglobulinemia (WM): As a single agent for the treatment of adult patients who have received at least one prior therapy or in first-line treatment for patients unsuitable for chemo-immunotherapy, and in combination with rituximab for the treatment of adult patients.
  • Fixed-Duration Ibrutinib Plus Venetoclax (I+V) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL): Primary Analysis of the Phase 3 GLOW Study.
  • Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study Leukemia.

European Hematology Association - ALPINE Study Reveals Superior Safety and Efficacy of Zanubrutinib Compared with Ibrutinib

Retrieved on: 
Friday, June 11, 2021
Orphan drugs, Chemical compounds, Breakthrough therapy, Piperidines, Drugs, Health sciences, Tyrosine kinase inhibitors, Tyrosine kinases, Bruton's tyrosine kinase, Ibrutinib, Zanubrutinib

Zanubrutinib is a next-generation BTK inhibitor that is designed for potent and sustained inhibition of BTK while minimizing the off-target effects of first-generation inhibitors such as ibrutinib.

Key Points: 
  • Zanubrutinib is a next-generation BTK inhibitor that is designed for potent and sustained inhibition of BTK while minimizing the off-target effects of first-generation inhibitors such as ibrutinib.
  • The activity and tolerability of zanubrutinib have been demonstrated in patients with CLL/SLL in early phase clinical trials.
  • The ALPINE study solidifies the findings of these pivotal trials by a head-to-head comparison of the safety and efficacy of zanubrutinib and ibrutinib in 415 patients with relapsed/refractory CLL/SLL.
  • In summary, zanubrutinib showed more selective inhibition of BTK resulting in improved efficacy and safety compared with ibrutinib.